TG-1701, a Novel Irreversible Bruton’s Kinase (BTK) Inhibitor, Cooperates with Ublituximab-Driven ADCC and ADCP in In Vitro and In Vivo Models of Ibrutinib-Resistant Mantle Cell Lymphoma By admin / 06/22/2020
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting By admin / 04/01/2019
TG-1601 is a Novel BET Inhibitor with Strong Binding Affinity and Long-lasting Effect in Pre-clinical Models By admin / 04/18/2018
Differential Regulation of Human T cells by TGR-1202, A Novel PI3K-delta Inhibitor. By admin / 04/16/2016
IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B-cell lymphomas. By admin / 04/18/2015
The PI3K Delta Inhibitor TGR-1202 Induces Cytotoxicity and Inhibits Phosphorylation of AKT in 17p Deleted and Non-17p Deleted CLL Cells in Vitro. By admin / 04/09/2014
The PI3K Delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines. By admin / 04/09/2014
The PI3k-delta inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro. By admin / 09/09/2013
Inhibition of PI3Kd kinase by a selective small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth. By admin / 04/04/2012
